On December 14, 2018, Astellas Pharma Inc. announced the closing of its acquisition of Potenza Therapeutics, Inc. The acquisition comes from a successful result of a collaboration agreement entered into in 2015 to build a portfolio of novel immune-oncology therapies. Through this research collaboration, Astellas and Potenza have discovered and developed three novel investigational drugs with the potential to treat various cancers that are non-responsive or resistant to the current generation of immune-oncology therapies.
The WilmerHale team representing Potenza in this transaction is led by Rosemary Reilly and includes Mark Nylen, Michael Lopes, Elizabeth Mayo and Jenny Moore.